Candesartan Cilexetil is refer to Biopharmaceutical classification system (BSC) class II which has low solubility as well as inadequate bioavailability. Candesartan Cilexetil nanosuspension was prepared to improve the solubility of Candesartan Cilexetil by using the antisolvent precipitation-ultrasonication method having different Solvent: Antisolvent Volume Ratio 1:15. PVP K-30 for was used as Stabilizer in candesartan cilexetil nanosuspension. Plackett-Burman design was utilized to determine which factor has the biggest impact on the quality, stability, and effectiveness of the nanosuspension. Mean particle size and saturation solubility, was assessed using 32 complete factorial design and other metrics including cumulative percentage released (CPR) at two minutes, zeta potential, polydispersity index (PDI), and percent weighted drug content was also assessed. Formulations of candesartan cilexetil nanosuspension batch CFD8 showed Mean Particle Size (nm) (Mean ± SD)( 240.7 ± 8.3) and Saturation Solubility (µg/ml) (Mean ± SD)(113.03 ± 2.51). Comparison was evaluated in-vitro dissolution of both nanosuspension with marketed formulation and un-milled suspension.